Superstring Capital Management LP 13F holdings, Q3 2025
Holdings as of September 30, 2025 · filings on SEC EDGAR · latest filing →
Superstring Capital Management LP disclosed 35 US equity positions worth $101.5m in its Q3 2025 13F filing. The largest position was ZLAB at 6.7% of the reported book, followed by CDTX and 430. Against the Q2 2025 filing, it opened 16 new positions, added to 7 and reduced 8 among the top 35 holdings.
What did Superstring Capital Management LP own in Q3 2025? Top 35 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q2 2025 |
|---|---|---|---|---|---|---|---|
| 1 | ZLAB ZAI LAB LTD | Healthcare | 6.7% | $6.8m | 200,628 | 49% | added |
| 2 | CDTX CIDARA THERAPEUTICS INC | 6.5% | $6.6m | 68,463 | – | new | |
| 3 | 430 TERNS PHARMACEUTICALS INC | 5.8% | $5.9m | 789,646 | -39% | reduced | |
| 4 | ETNBGBP 89BIO INC | 5.6% | $5.7m | 384,652 | 81% | added | |
| 5 | IMVT IMMUNOVANT INC | Healthcare | 5.4% | $5.5m | 341,348 | – | new |
| 6 | JAZZ JAZZ PHARMACEUTICALS PLC | Healthcare | 5.3% | $5.4m | 40,893 | -7% | reduced |
| 7 | COGT COGENT BIOSCIENCES INC | Healthcare | 5.1% | $5.2m | 361,408 | -62% | reduced |
| 8 | SVRA SAVARA INC | Healthcare | 4.6% | $4.7m | 1,309,236 | 17% | added |
| 9 | BBIO BRIDGEBIO PHARMA INC | Healthcare | 4.5% | $4.6m | 88,658 | -8% | reduced |
| 10 | SMMT SUMMIT THERAPEUTICS INC | Healthcare | 4.0% | $4.1m | 197,253 | – | new |
| 11 | IQV IQVIA HLDGS INC | Healthcare | 3.6% | $3.6m | 19,114 | – | new |
| 12 | CABA CABALETTA BIO INC | Healthcare | 3.6% | $3.6m | 1,544,525 | 46% | added |
| 13 | REGN REGENERON PHARMACEUTICALS | Healthcare | 3.5% | $3.6m | 6,401 | – | new |
| 14 | DRUG BRIGHT MINDS BIOSCIENCES INC | Healthcare | 3.2% | $3.3m | 53,950 | – | new |
| 15 | NKTR NEKTAR THERAPEUTICS | Healthcare | 2.9% | $2.9m | 51,270 | – | new |
| 16 | INSM INSMED INC | Healthcare | 2.8% | $2.8m | 19,786 | 36% | added |
| 17 | BCAX BICARA THERAPEUTICS INC | 2.7% | $2.8m | 175,902 | -7% | reduced | |
| 18 | AVTX AVALO THERAPEUTICS INC | Healthcare | 2.4% | $2.4m | 188,080 | – | new |
| 19 | SNY SANOFI SA | 2.3% | $2.4m | 50,407 | – | new | |
| 20 | ZBIO ZENAS BIOPHARMA INC | 2.1% | $2.1m | 96,665 | -13% | reduced | |
| 21 | QURE UNIQURE NV | 1.9% | $1.9m | 33,175 | – | new | |
| 22 | TECX TECTONIC THERAPEUTIC INC | Healthcare | 1.8% | $1.9m | 119,286 | 51% | added |
| 23 | URGN UROGEN PHARMA LTD | Healthcare | 1.7% | $1.8m | 87,912 | 0% | held |
| 24 | TARA PROTARA THERAPEUTICS INC | 1.5% | $1.6m | 360,000 | 0% | held | |
| 25 | KROS KEROS THERAPEUTICS INC | Healthcare | 1.5% | $1.5m | 95,083 | – | new |
| 26 | SRRK SCHOLAR ROCK HLDG CORP | Healthcare | 1.4% | $1.5m | 39,521 | – | new |
| 27 | PTGX PROTAGONIST THERAPEUTICS INC | Healthcare | 1.3% | $1.4m | 20,358 | – | new |
| 28 | TVTX TRAVERE THERAPEUTICS INC | Healthcare | 1.3% | $1.3m | 53,627 | -81% | reduced |
| 29 | ORIC ORIC PHARMACEUTICALS INC | Healthcare | 1.1% | $1.1m | 89,346 | -74% | reduced |
| 30 | RAPT RAPT THERAPEUTICS INC | 0.9% | $888.4k | 34,449 | 32% | added | |
| 31 | VIR VIR BIOTECHNOLOGY INC | Healthcare | 0.8% | $858.3k | 150,312 | – | new |
| 32 | CRBP CORBUS PHARMACEUTICALS HLDGS | Healthcare | 0.7% | $729.2k | 57,644 | – | new |
| 33 | NBP I MAB | Healthcare | 0.5% | $528.8k | 139,886 | – | new |
| 34 | BMEA BIOMEA FUSION INC | 0.5% | $505.0k | 250,000 | 0% | held | |
| 35 | IPSC CENTURY THERAPEUTICS INC | Healthcare | 0.2% | $230.6k | 462,963 | 0% | held |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.